Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Darken

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Respiratory Research|September 3, 2016
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPDLeonardo M Fabbri, Edward M Kerwin, Selwyn Spangenthal, et al.
Respiratory Medicine|July 23, 2017
Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24]Donald P Tashkin, Fernando J Martinez, Roberto Rodriguez-Roisin, et al.
Respiratory Medicine|November 8, 2016
A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPDDonald P Tashkin, Fernando J Martinez, Roberto Rodriguez-Roisin, et al.
Respiratory Research|August 23, 2017
Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
Respiratory Research|January 8, 2017
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
Chest|December 6, 2016
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPDFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
American Journal of Respiratory and Critical Care Medicine|October 21, 2021
Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move ForwardFernando J Martinez, Alvar Agusti, Bartolome R Celli, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Respiratory Research|September 3, 2016
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPDLeonardo M Fabbri, Edward M Kerwin, Selwyn Spangenthal, et al.
Respiratory Medicine|July 23, 2017
Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24]Donald P Tashkin, Fernando J Martinez, Roberto Rodriguez-Roisin, et al.
Respiratory Medicine|November 8, 2016
A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPDDonald P Tashkin, Fernando J Martinez, Roberto Rodriguez-Roisin, et al.
Respiratory Research|August 23, 2017
Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
Respiratory Research|January 8, 2017
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
Chest|December 6, 2016
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPDFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
American Journal of Respiratory and Critical Care Medicine|October 21, 2021
Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move ForwardFernando J Martinez, Alvar Agusti, Bartolome R Celli, et al.
Pageof 5